Vitiello, Pietro Paolo
Cardone, Claudia
Martini, Giulia
Ciardiello, Davide
Belli, Valentina
Matrone, Nunzia
Barra, Giusi
Napolitano, Stefania
Della Corte, Carmina
Turano, Mimmo
Furia, Maria
Troiani, Teresa
Morgillo, Floriana
De Vita, Ferdinando
Ciardiello, Fortunato
Martinelli, Erika
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (MFAG-2015-ID:7778, IG-2013-ID:14800)
Article History
Received: 27 October 2018
Accepted: 10 January 2019
First Online: 28 January 2019
Ethics approval and consent to participate
: not applicable.
: all authors agree on publication of the results of the present manuscript.
: EM: advisory board for Amgen, Bayer, Merck, Roche, Sanofi, Servier, Biocartis and expert opinion for ESMO (European Society of Medical Oncology). TT: advisory board for Amgen, Bayer, Merck, Novartis, Roche, Sanofi. FM: advisory board for Lilly, MSD. FDV: advisory board for Amgen, Lilly, Roche, Celgene. FC: advisory board for Merck, Roche, Amgen, Bayer, Servier, Symphogen,Pfizer and research funding from Roche, Merck, Amgen, Bayer, Ipsen. PPV, GM, DC, CC, CDC, ST, VB, NM, GB, MF, MT declare no competing conflict of interest regarding the following manuscript.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.